Pharmacy Times

JUNE 18, 2025

The Healthy People 2030 initiative addresses structural health care inequalities and implements programs to ameliorate SDOH. Healthy People 2030. Each unique set of economic, educational, social, and environmental circumstances significantly affects their quality of life and health. REFERENCES 1. Social determinants of health.

Immunization 65

Immunization Compounding Pharmacies Hospitals Chemotherapy 65

Pharmacy Times

JUNE 9, 2025

2019;380:2020-2030. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. N Engl J Med. Subscribe Now!

Compounding Pharmacies 73

Compounding Pharmacies Hospitals Immunization Chemotherapy 73

Pharmacy Times

JUNE 19, 2025

With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. Trends Pharmacol Sci. 2024;45(5):406-418.

Compounding 65

Compounding Compounding Pharmacies FDA Immunization 65

Pharmaceutical Technology

JULY 4, 2025

How will RFK Jr’s American dream for vaccines play out? Imfinzi is now approved to treat adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with chemotherapy drugs gemcitabine and cisplatin as neoadjuvant treatment, and as a monotherapy after bladder removal surgery.

Chemotherapy 52

Chemotherapy Packaging Communication Labelling 52

The Checkup by Singlecare

AUGUST 3, 2023

The costs are expected to increase to $246 billion by the year 2030. billion in out-of-pocket expenses for their surgery, radiation, and chemotherapy. These are the most common types of cancer treatment : Chemotherapy: Many people get treated with chemotherapy drugs that kill or shrink cancer cells. in 2023. (

Chemotherapy 98

Chemotherapy Hospitals Insurance Immunization 98

PharmTech

JULY 7, 2025

billion) by 2030 (1). Osimertinib (Tagrisso, AstraZeneca ) was accepted, together with chemotherapy, for first-line treatment of adults with advanced non-small cell lung cancer in which the cancer cells have mutations in exon 19 or exon 21 of the EGFR gene. billion (US$6.3

Dosage 49

Dosage Chemotherapy Vaccines 49

Pharmaceutical Technology

JULY 4, 2025

How will RFK Jr’s American dream for vaccines play out? Robert Barrie July 4, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Only 4% of global drugs sales in 2030 will have patent protection. A recent report by GlobalData projects that the share of global drug sales under patent protection will decline by 2030.

Chemotherapy 52

Chemotherapy Packaging Communication Hospitals 52